Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04484779 · ClinicalTrials.gov registry record · NA
A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes
A NA study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- NA
- Development phase
- 67
- Enrollment target
NCT04484779 is a NA study that has completed, run by Eli Lilly and Company. The registered enrollment target is 67 participants.
The verdict
NCT04484779, a NA study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- NA
- Development phase
- 67 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the user experience of an integrated insulin management system (IIM) in participants with type 1 or type 2 diabetes. The IIM system is comprised of an insulin injection pen with a data transmission module and blood glucose meter which are connected to a mobile phone application. The application will be used to record and track diabetes-data related information.
Interventions
- DEVICE IIM System
- DRUG Insulin Lispro and/or Insulin Glargine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2020-07-14 |
| Est. Completion | 2020-12-22 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04484779
The ClinicalTrials.gov registry entry for NCT04484779 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IIM System is the first listed.
NCT04484779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04484779 about?
NCT04484779 is a clinical study titled "A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes". The purpose of this study is to investigate the user experience of an integrated insulin management system (IIM) in participants with type 1 or type 2 diabetes. The IIM system is comprised of an insulin injection pen with a data transmission module and blood glucose meter which are connected to a mo...
What is the current status of trial NCT04484779?
This trial is currently completed. It is a NA study. The enrollment target is 67 participants. The study started on 2020-07-14. Estimated completion is 2020-12-22.
What interventions are being tested in trial NCT04484779?
The interventions under investigation include: IIM System (DEVICE), Insulin Lispro and/or Insulin Glargine (DRUG).
Who is sponsoring clinical trial NCT04484779?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.